Galectin Therapeutics

The NAVIGATE trial of Galectin Therapeutics' belapectin for MASH cirrhosis and portal hypertension missed its primary endpoint for varices prevention. Belapectin reduced varice incidence but not significantly. Further analysis and 36-month treatment data expected in 2025.

Galectin Therapeutics' stock dropped 35% after its lead asset, Belapectin, failed to reach the primary endpoint in a Phase IIb/III trial for MASH cirrhosis. While Belapectin reduced varices incidence by 48.9% in the per-protocol population, it fell short of the 52.5% target. The drug showed a highly encouraging safety profile and potential in advanced melanoma. Galectin plans to analyze 36-month outcomes before determining next steps.

DelveInsight's report on Nonalcoholic Steatohepatitis (NASH) provides insights into historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2019 to 2032 in the United States, EU5, and Japan. Key companies and therapies in the NASH market are highlighted, including recent developments like Aligos Therapeutics' Phase 1 data presentation.